<DOC>
	<DOCNO>NCT00430118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat young patient acute lymphoblastic leukemia . PURPOSE : Thisphase III trial study several different combination chemotherapy regimens compare well work treat young patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Based Risk Relapse Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare relative efficacy induction therapy comprise dexamethasone prednisone , term high rate event-free survival ( EFS ) overall survival reduce rate relapse , pediatric patient intermediate-risk high-risk acute lymphoblastic leukemia ( ALL ) . - Compare relative safety reduced-intensity reintensification regimen comprise dexamethasone , vincristine , cyclophosphamide , anthracyclines vs standard treatment regimen pediatric patient standard-risk ALL identify fast clearance leukemic cell . - Compare efficacy second delayed reintensification regimen vs standard reintensification therapy , term improve EFS , pediatric patient intermediate-risk ALL . - Compare efficacy extend reintensification therapy ( triple reinduction ) v standard reintensification therapy ( intensive pulse one reintensification ) pediatric patient high-risk ALL . OUTLINE : This randomize , multicenter study . - Prednisone prephase therapy : Patients receive oral prednisone day 1-7 one dose methotrexate ( MTX ) intrathecally ( IT ) day 1 . - Induction/consolidation therapy , protocol I : Patients randomize 1 2 treatment arm . - Arm I ( close accrual 6/30/2006 ) : Patients receive prednisone ( PRED ) day 8-28 . - Arm II ( close accrual 6/30/2006 ) : Patients receive dexamethasone ( DEXA ) day 8-28 . Patients arm also receive vincristine ( VCR ) daunorubicin hydrochloride ( DNR ) weekly week 2-5 ; asparaginase ( ASP ) day 12-33 ; cyclophosphamide ( CPM ) day 36 64 ; cytarabine ( ARA-C ) week 6-9 ; mercaptopurine ( MP ) day 36-63 ; MTX IT day 1 , 12 , 33 , 45 , 59 . * NOTE : *Patients CNS disease also receive MTX IT day 18 27 . After completion induction/consolidation therapy , patient stratify accord risk group base disease response ( standard-risk [ SR ] group [ negative minimal residual disease ( MRD ) day 33 protocol M , day 78 ] vs high-risk [ HR ] group [ MRD ≥ 10^-³ day 78 ] vs intermediate-risk [ IR ] group [ nonSR/nonHR ] ) . * Patients SR IR disease proceed extracompartment therapy . Patients HR disease proceed reintensification therapy . NOTE : *Patients meet follow criterion place HR group regardless MRD response : Philadelphia chromosome-positive disease ( BCR/ABL [ 9 ; 22 ] ; translocation [ t4 ; 11 ] [ q11 ; q23 ] MLL/AF4 ) ; `` prednisone-poor-response '' ( ≥ 1,000 blasts/mm³ peripheral blood day 8 prednisone prephase therapy ) ; response study induction therapy ( M2/3 day 33 ) . - Extracompartment therapy , protocol M : Patients receive MP day 1-56 MTX day 8 , 22 , 36 , 50 . After completion extracompartment therapy , SR IR patient proceed reintensification therapy . SR patient randomize arm I II . IR patient randomize arm I III . HR patient complete induction/consolidation therapy randomize arm IV V. - Reintensification therapy : - Arm I ( standard reinduction therapy , protocol II [ close accrual 6/30/2006 ] ) : SR IR patient receive DEXA day 1-22 ; VCR doxorubicin hydrochloride ( DOX ) week 2-5 ; ASP day 8 , 11 , 15 , 18 ; CPM day 36 ; ARA-C thioguanine ( TG ) day 36-49 ; MTX IT day 38 45 . * Patients proceed maintenance therapy . NOTE : *Patients CNS disease also receive MTX IT day 1 18 . - Arm II ( reduced-intensity reinduction therapy , protocol III [ close accrual 6/30/2006 ] ) : SR patient receive DEXA day 1-15 ; VCR DOX day 1 8 ; ASP day 1 , 4 , 8 , 11 ; CPM day 15 ; ARA-C TG day 15-28 ; MTX IT day 17 24 . * Patients proceed maintenance therapy . NOTE : *Patients CNS disease also receive MTX day 1 . - Arm III ( reduced-intensity reinduction/second delay reinduction therapy [ double reintensification therapy ] [ close accrual 6/30/2006 ] ) : IR patient receive reduced-intensity reintensification therapy arm II . After 10-week interim maintenance phase , treatment repeat second delayed course reintensification therapy . Patients proceed maintenance therapy . - Arm IV ( standard reintensification therapy [ close accrual 6/30/2006 ] ) : HR patient receive two sequence follow HR therapy element ( i.e. , order : 1 , 2 , 3 , 1 , 2 , 3 ) follow reintensification therapy arm I . Patients proceed maintenance therapy . - Element HR-1 : Patients receive DEXA day 1-5 ; VCR day 1 6 ; ARA-C twice day 5 ; MTX CPM every 12 hour day 2-4 ( 5 dos ) ; ASP day 6 11 ; MTX/ARA-C/PRED IT day 1 . - Element HR-2 : Patients receive DEXA day 1-5 ; vindesine day 1 6 ; DNR day 5 ; MTX ifosfamide every 12 hour day 2-4 ( 5 dos ) ; ASP day 6 11 ; MTX/ARA-C/PRED IT day 1 . * NOTE : *HR patient CNS disease also receive IT therapy day 5 . - Element HR-3 : Patients receive DEXA day 1-5 ; ARA-C every 12 hour day 1-2 ( 4 dos ) ; etoposide five time daily day 3-5 ; ASP day 6 11 ; MTX/ARA-C/PRED IT day 1 . - Arm V ( extend reintensification therapy [ triple protocol III ] [ close accrual 6/30/2006 ] ) : HR patient receive HR therapy element 3 , 2 , 1 arm IV follow reintensification therapy arm II repeat therapy element twice 4-week interim maintenance phase . Patients proceed maintenance therapy . - Interim maintenance/maintenance therapy : Patients receive MTX weekly MP daily week 104 . - Radiotherapy : HR patient patient T-cell acute lymphoblastic leukemia CNS disease undergo CNS radiotherapy . PROJECTED ACCRUAL : A total 2,000 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) No secondary ALL PATIENT CHARACTERISTICS : No prior disease would preclude treatment chemotherapy PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy More 4 week since prior steroid</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>